Amgen
AMGN
$0.91 (0.32%)
1D
1W
3M
1Y
5Y
ALL
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
The Motley Fool • 1 day ago • AMGN
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-OffReuters • 2 days ago • AMGN
Amgen to expand Ohio biotech manufacturing plantPRNewsWire • 2 days ago • AMGN
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIOZacks Investment Research • 4 days ago • AMGN
Amgen (AMGN) Earnings Expected to Grow: Should You Buy?Barrons • 6 days ago • AMGN
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs LoomCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.